Skip to main content
. 2020 Jul 25;9(4):889–911. doi: 10.1007/s40123-020-00280-8

Fig. 6.

Fig. 6

Change in BCVA over time with belamaf treatment in the DREAMM-2 case report. BCVA best-corrected visual acuity, KVA keratopathy and visual acuity, MECs microcyst-like epithelial changes. Corneal examination finding (MECs and changes in BCVA) were graded per KVA scale (Table 1), and represented (as grades 1–4) above each line for each examination